Subsidiary of Hunan Dajiaweikang Pharmaceutical Industry (301126.SZ) receives azithromycin dry powder for oral suspension drug registration certificate.

Hunan Dajiaweikang Pharmaceutical Industry (301126.SZ) announced that its wholly-owned subsidiary, Hunan Dajiaweikang Pharmaceutical Industry Biopharmaceutical Co., Ltd., has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the azithromycin dry suspension. Indications for azithromycin dry suspension include the following: Azithromycin is a macrolide antibiotic used to treat mild to moderate infections caused by specified sensitive strains of microorganisms in the following specific conditions: 1. Acute exacerbation of chronic bronchitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. 2. Community-acquired pneumonia caused by Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae. 3. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. 4. Acute bacterial sinusitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. 5. Pharyngitis/tonsillitis caused by Streptococcus pyogenes. 6. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. 7. Urethral and cervical infections caused by Chlamydia trachomatis or Neisseria gonorrhoeae. 8. Genital ulcer disease (soft chancre) caused by Haemophilus ducreyi. The efficacy of azithromycin in treating female soft chancre has not yet been determined due to the small number of female participants in clinical trials.